Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Implantable prosthesis – Tissue
Reexamination Certificate
2005-12-06
2005-12-06
Philogene, Pedro (Department: 3732)
Prosthesis (i.e., artificial body members), parts thereof, or ai
Implantable prosthesis
Tissue
C623S011110, C623S023630
Reexamination Certificate
active
06972041
ABSTRACT:
The invention provides an article of manufacture comprising a substantially non-immunogenic bone xenograft for implantation into humans. The invention further provides a method for preparing a bone xenograft by removing at least a portion of a bone from a non-human animal to provide a xenograft (X); washing the xenograft in saline and alcohol; subjecting the xenograft to a cellular disruption treatment; and treating the xenograft with a glycosidase to remove surface carbohydrate moieties. The invention also provides an article of manufacture produced by the above identified method of invention. The invention further provides a bone xenograft for implantation into a human including a portion (10) of a bone from a nonhuman animal, wherein the portion has substantially no surface carbohydrate moieties which are susceptible to glycosidase digestion. Each xenograft of the invention has substantially the same mechanical properties as a corresponding native bone.
REFERENCES:
patent: 4400833 (1983-08-01), Kurland
patent: 4585585 (1986-04-01), Waite
patent: 4597266 (1986-07-01), Entrekin
patent: 4609627 (1986-09-01), Goldstein
patent: 4627853 (1986-12-01), Campbell et al.
patent: 4642120 (1987-02-01), Nevo et al.
patent: 4678470 (1987-07-01), Nashef et al.
patent: 4755593 (1988-07-01), Lauren
patent: 4789663 (1988-12-01), Wallace et al.
patent: 4801299 (1989-01-01), Brendel et al.
patent: 4880429 (1989-11-01), Stone
patent: 4932973 (1990-06-01), Gendler
patent: 5067962 (1991-11-01), Campbell et al.
patent: 5071741 (1991-12-01), Brockbank
patent: 5131850 (1992-07-01), Brockbank
patent: 5160313 (1992-11-01), Carpenter et al.
patent: 5171660 (1992-12-01), Carpenter et al.
patent: 5192312 (1993-03-01), Orton
patent: 5206023 (1993-04-01), Hunziker
patent: 5216126 (1993-06-01), Cox et al.
patent: 5306304 (1994-04-01), Gendler
patent: 5333626 (1994-08-01), Morse et al.
patent: 5516532 (1996-05-01), Atala et al.
patent: 5613982 (1997-03-01), Goldstein
patent: 5632778 (1997-05-01), Goldstein
patent: 5681353 (1997-10-01), Li et al.
patent: 5782915 (1998-07-01), Stone
patent: 5865849 (1999-02-01), Stone
patent: 5902338 (1999-05-01), Stone
patent: 5904716 (1999-05-01), Gendler
patent: 5922027 (1999-07-01), Stone
patent: 5944755 (1999-08-01), Stone
patent: 5984858 (1999-11-01), Stone
patent: 6046379 (2000-04-01), Stone et al.
patent: 6049025 (2000-04-01), Stone et al.
patent: 6110206 (2000-08-01), Stone
patent: 6113603 (2000-09-01), Medoff
patent: 6231608 (2001-05-01), Stone
patent: 347496 (1989-12-01), None
patent: WO 84/03036 (1984-08-01), None
patent: WO 95/26740 (1995-10-01), None
patent: WO 95/28412 (1995-10-01), None
patent: WO 95/33828 (1995-12-01), None
Rodrigo et al., “Osteocartilaginous Allografts as Compared with Autografts in the Treatment of Knee Joint Osteocartilaginous Defects in Dogs”, Clinical Orthopedics and Related Research, 134, pp. 342-349 (1978).
Webber et al., “Cell Culture of Rabbit Meniscal Fibrochondrocytes: Proliferative and Synthetic Response to Growth Factors and Ascorbate”, Journal of Orthopedic Research, 3, pp. 36-42 (1985).
Collins et al., “Characterization of Porcine Endothelial Cell Determinants Recognized by Human Natural Antibodies”, Xenotransplantation, 1, pp. 36-46 (1994).
LaVecchio et al., “Enzymatic Removal of Alpha-Galactosyl Epitopes From Porcine Endothelial Cells Diminishes The Cytotoxic Effect of Natural Antibodies”, Transplantation, 60, pp. 841-847 (1995).
Cotterell et al., “The Humoral Immune Response in Humans Following Cross-Perfusion of Porcine Organs”, Transplantation, 60, pp. 861-868 (1995).
Galili, “Interaction of the Natural Anti-Gal Antibody with α-Galactosyl Epitopes: a Major Obstacle for Xenotransplantation in Humans”, Immunology Today, 14, pp. 480-482 (1993).
Elves et al., “An Investigation Into The Immunogenicity Of Various Components of Osteoarticular Grafts”, The British Journal of Experimental Pathology, 55, pp. 344-351 (1974).
Derby et al., “The Histochemical Specificity of Streptomyces Hyaluronidase and Chondroitinase ABC”, Histochemical Journal, 10, pp. 529-547 (1978).
Homandberg et al., “High Concentrations of Fibronectin Fragments Cause Short-Term Catabolic Effects in Cartilage Tissue While Lower Concentrations Cause Continuous Anabolic Effects”, Archives of Biochemistry and Biophysics, 311:2, pp. 213-218 (1994).
Homandberg et al., “Agents That Block Fibronectin Fragment-Mediated Cartilage Damage Also Promote Repair”, Inflamm. Res., 46, pp. 467-471 (1997).
Homandberg et al., “Exposure of Cartilage to a Fibronectin Fragment Amplifies Catabolic Processes While Also Enhancing Anabolic Processes to Limit Damage”, Journal of Orthopaedic Research, 16, pp. 237-246 (1998).
Homandberg et al., “Association of Proteoglycan Degradation with Catabolic Cytokine and Stromelysin Release from Cartilage Cultured with Fibronectin Fragments”, 334:2, pp. 325-331 (1996).
Lipman et al., “Xenografts of Articular Chondrocytes in the Nude Mouse”, Calcif. Tissue Int., 35, pp. 767-772 (1983).
Stone et al., “Porcine and Bovine Cartilage Transplants in Cynomolgus Monkey: I. A Model for Chronic Xenograft Rejection”, Transplantation, 63, pp. 640-645 (1997).
Galili et al., “Porcine and Bovine Cartilage Transplants in Cynomolgus Monkey: II. Changes in Anti-Gal Response During Chronic Rejection”, Transplantation, 63, pp. 646-651 (1997).
Stedman's Medical Dictionary, Williams & Wilkins, 26 ed., pp. 221, 793, 1070, 1966 (1995).
Galili et al., “Man, Apes, and Old World Monkeys Differ from Other Mammals in the Expression of α-Galactosyl Epitopes on Nucleated Cells”, J. Biol. Chem., 263, 17755-17762 (1988).
J.M. Lane, et al., “Current Approaches to Experimental Bone Grafting”, Orthopedic Clinics of North America 18, pp. 213-225 (1987).
U. Galili et al., “Interaction Between Human Natural Anti-α-Galactosyl Immunoglobulin G and Bacteria of The Human Flora”, Infect. Immun. 56, 1730-1737 (1988).
R.M. Hamadeh et al., “Human Natural Anti-Gal IgG Regulates Alternative Complement Pathway Activation on Bacterial Surfaces”, J. Clin. Invest. 89, 1223-1235 (1992).
M. Sandrin et al., “Anti-Pig IgM Antibodies in Human Serum React Predominantly With Gal (αl-3) Gal Epitopes”, Proc. Natl. Acad. Sci USA 90, 11391-11395 (1993).
H. Good et al., “Identification of Carbohydrate Structures That Bind Human Antiporcine Antibodies: Implications for Discordant Xenografting In Humans”, Transplant. Proc. 24, 559-562 (1992).
B.H. Collins, et al., “Cardiac Xenografts Between Primate Species Provide Evidence for the Importance of the α-Galactosyl Determinant in Hyperacute Rejection”, J. Immunol. 154, 5500-5510 (1995).
S. Stevenson et al., “The Effect of Osteogenin (a Bone Morphogenetic Protein) on the Formation of Bone In Orthotopic Segmental Defects in Rats”, Journal of Bone and Joint Surgery No. 76, 1676-1687 (1994).
J. Feighan, et al., “Induction of Bone by a Demineralized Bone Matrix Gel: A Study in a Rat Femoral Defect Model”, Journal of Orthopaedic Research 13, 881-891 (1995).
R.G. Spiro et al., “Occurrence of α-D-Galactosyl Residues in the Thyroglobulin from Several Species. Localization in the Saccharide Chains of the Complex Carbohydrate Units”, J. Biol. Chem. 259, 9858-9866 (1984).
R.G. Arumugham et al., “Structures of the Asparagine-Linked Sugar Chains of Laminin.”, Biochem. Biophys. Acta 883, 112-126 (1986).
CrossCart, Inc.
Philogene Pedro
LandOfFree
Bone xenografts does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bone xenografts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bone xenografts will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3493960